Almost a year ago, China’s Shanghai Henlius Biotech achieved a major milestone for Chinese biosimilars by obtaining the first approval from the country’s National Medical Products Administration for its rituximab biosimilar, HLX01.
Shanghai Henlius CEO Wants To Capitalize On First-Mover Status
Scott Liu Sets Out Ambitions That Go Beyond China
In an exclusive interview with Generics Bulletin, Dr. Scott Liu, co-founder, and CEO of Chinese biosimilars and biologics specialist Shanghai Henlius Biotech, has set out his vision for the firm’s future in China and around the globe.
More from Strategy
More from Business
• By
Generics Bulletin previews the most noteworthy and anticipated events for May 2025.
• By
Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.
• By
Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.